In this NKCE, a humanized anti-CD16a VHH fragment, instead of the conventional anti-CD16a scFv, was incorporated into the NKCE and could mediate efficient NK cell activation and tumor cell lysis (61). The gene discussed is FCGR3A; the disease is neoplasm.